Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing

FDA hearing officer Karen Midthun rejects the Center for Drug Evaluation and Research's request to bar evidence on discussions over a new study of Avastin in first-line metastatic breast cancer.